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Abstract
Background: BACE1 is a key enzyme in the generation of the Ab peptide that plays a central role in the
pathogenesis of Alzheimer’s disease. While BACE1 is an attractive therapeutic target, its normal physiological
function remains largely unknown. Examination of BACE1
-/- mice can provide insight into this function and also
help anticipate consequences of BACE1 inhibition. Here we report a seizure-susceptibility phenotype that we have
identified and characterized in BACE1
-/- mice.
Results: We find that electroencephalographic recordings reveal epileptiform abnormalities in some BACE1
-/- mice,
occasionally including generalized tonic-clonic and absence seizures. In addition, we find that kainic acid injection
induces seizures of greater severity in BACE1
-/- mice relative to BACE1
+/+ littermates, and causes excitotoxic cell
death in a subset of BACE1
-/- mice. This hyperexcitability phenotype is variable and appears to be manifest in
approximately 30% of BACE1
-/- mice. Finally, examination of the expression and localization of the voltage-gated
sodium channel a-subunit Nav1.2 reveals no correlation with BACE1 genotype or any measure of seizure
susceptibility.
Conclusions: Our data indicate that BACE1 deficiency predisposes mice to spontaneous and pharmacologically-
induced seizure activity. This finding has implications for the development of safe therapeutic strategies for
reducing Ab levels in Alzheimer’s disease. Further, we demonstrate that altered sodium channel expression and
axonal localization are insufficient to account for the observed effect, warranting investigation of alternative
mechanisms.
Background
Alzheimer’s disease (AD) is a common and devastating
neurodegenerative disorder involving a decline in mem-
ory and other cognitive functions. Disease modifying
therapies for AD are greatly needed, but remain elusive.
One promising approach to such a therapy is to inhibit
the production of the b-amyloid (Ab) peptide, which is
the primary constituent of amyloid plaques that repre-
sent a major histopathological hallmark of AD [1,2].
Mutations that cause autosomal dominant familial AD
(FAD) all lead to increased production of Ab,p a r t i c u -
larly in its 42-amino acid isoform (Ab42) (reviewed in
[3]). This and other lines of evidence strongly suggest
that Ab plays a central and early role in AD pathogen-
esis (reviewed in [4]).
Ab is produced through the endoproteolysis of the
amyloid precursor protein (APP) by two proteases, the
b- and g-secretases (reviewed in [5]). APP is first cleaved
by the b-secretase at the N-terminus of Ab to produce
the membrane-bound C99 fragment, which is further
cleaved by g-secretase to release Ab. The b-secretase has
been identified as a transmembrane aspartic protease
referred to as BACE1 [6-10]. Because of its role in Ab
production, BACE1 is a promising drug target for AD.
This is highlighted by the finding that Ab generation,
amyloid pathology, electrophysiological dysfunction, and
cognitive deficits characteristic of APP transgenic mice
are all abrogated by genetic deletion of BACE1 [11-15].
The normal function of BACE1 remains largely
unknown, and a better understanding of its function(s)
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of BACE1 inhibition as a therapeutic strategy. In addi-
tion to APP, several other BACE1 substrates have been
identified which may mediate the normal function of
BACE1. These include a2,6-sialyltransferase [16], P-
selectin glycoprotein ligand-1 (PSLG-1) [17], the APP
homolog proteins APLP1 and APLP2 [18-20], low-den-
sity lipoprotein receptor-related protein (LRP) [21], the
voltage-gated sodium channel b2 subunit (Navb2)
[22,23], neuregulin-1 (NRG1) [24,25] and neuregulin 3
(NRG3) [26]. We can also infer normal functions of
BACE1 from deficits observed in the BACE1
-/- mouse
lines that have been generated [11,27-29]. For instance,
impaired performance in certain memory tasks suggests
that BACE1 may play a role in memory [12,13]. In addi-
tion, reduced cleavage of NRG1 in BACE1
-/- mice has
been shown to lead to hypomyelination in the central
and peripheral nervous systems, as well as impaired
remyelination following nerve injury [24-26]. This abro-
gated cleavage of NRG1, which is genetically linked to
schizophrenia, has also been implicated in schizophre-
nia-like phenotypes described in BACE1
-/- mice [30].
BACE1 may, via its cleavage of Navb2, affect the
expression and function of voltage-gated sodium chan-
nels (VGSCs) and thus modulate membrane excitability.
VGSCs are composed of a single pore-forming a-subu-
nit and either one or two accessory b-subunits (reviewed
in [31]). The b-subunits interact directly with the a-sub-
units to affect localization, cell-surface expression and
inactivation of the VGSC [32] (reviewed in [31,33]).
There are four b-subunits (b1-4), all of which appear to
be cleaved by BACE1 [22,23]. Ten a subunits are
known, four of which are notably found in the CNS:
Nav1.1 and Nav1.3 in the neuronal soma and dendrite,
and Nav1.2 and Nav1.6 in the axon (reviewed in [34]).
BACE1 cleavage of b2 has been reported to increase
expression of Nav1.1 in vitro and in vivo,t h o u g hc e l l
surface expression is reduced as the channel is retained
intracellularly [35]. Interestingly, another study found
that BACE1 alters sodium channel gating, leading to
increased excitability, in a manner independent of pro-
teolytic activity [36].
We have previously reported an increased sensitivity
of BACE1
-/- mice to kainic acid-induced seizures [37].
Here we further characterize the seizure-susceptibility
phenotype we have observed in BACE1
-/- mice. We
report that a subset of these mice demonstrate abnormal
background activity and spiking on EEG recording and a
smaller subset display spontaneous tonic-clonic seizures.
In addition, we find some BACE1
-/- mice to be particu-
larly susceptible to pharmacologically induced seizures
and excitotoxic injury. The previously reported regula-
tion of VGSCs by BACE1 is an interesting candidate for
an underlying mechanism of this phenotype, since
mutations in both a and b-subunits have been linked to
epilepsy [38-43] (reviewed in [44]). However, we find
that neither total brain nor hippocampal protein nor
axonal expression levels of sodium channels correlate
with measures of seizure susceptibility in BACE1
-/-
mice. Overall, our results suggest that BACE1 deficiency
predisposes mice to neuronal hyperexcitability and that
alterations of VGSC expression and axonal localization
are insufficient to account for this effect.
Results
BACE1
-/- mice have spontaneous seizures and other EEG
abnormalities
In the course of maintaining the BACE1
-/- mice, we
observed rare instances of spontaneous seizure-like
behavior. To document and characterize these events,
we recorded simultaneous EEG/video in BACE1
-/-
mice at 3 months of age. A total of 16 BACE1
-/- mice
were recorded continuously for five days. Whereas 11
of the 16 BACE1
-/- mice exhibited no epileptiform
abnormalities or behavioral seizures, background EEG
recordings in 5 of the 16 BACE1
-/- mice (Fig. 1A)
revealed a heterogeneous mixture of epileptiform
abnormalities that included single spike and polyspike
abnormalities, as well as spike-wave discharges (SWD)
(Fig. 1B) similar to those reported in mouse models of
generalized absence epilepsy [45,46]. SWDs were
o b s e r v e di n4o ft h e5B A C E 1
-/- mice with abnormal
EEG activity and occurred on average 85.6+3.4 events/
hr during awake behavior, with spike frequency during
discharges 5.8+1.2 Hz. Many, but not all of the SWDs
observed on EEG were associated with distinct beha-
vioural pauses, similar to findings in other models of
generalized absence epilepsy [46]. Of the 5 BACE1
-/-
mice exhibiting epileptiform background activity,
2 were observed to have electrographic and beha-
vioural generalized tonic-clonic seizures (Fig. 1C; addi-
tional file 1: Video 1). Interestingly, all of the
generalized tonic-clonic seizures in BACE1
-/- mice
began during non-REM sleep, and were characterized
by an abrupt loss of muscle tone (atonia) lasting 2-3
seconds (additional file 2: Video 2), followed immedi-
ately by tonic-clonic convulsions lasting from 1-4 min-
utes. Electrographically, seizures were characterized by
an abrupt suppression of background EEG amplitude
coincident with atonia, followed by continuous, large
amplitude 6-8 Hz spike-wave activity that was accom-
panied by generalized convulsion. After convulsions,
BACE1
-/- mice showed decreased movement and atte-
nuated EEG amplitude lasting 1-2 minutes.
SWDs and absence seizures in mice and human
patients can be reduced or prevented by treatment with
the T-type Ca
2+-channel antagonist, ethosuximide
[46-48], whereas sodium channel antagonists such as
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Pharmacological studies in BACE1
-/- mice exhibiting
SWDs revealed that whereas phenytoin had no effect on
spike-wave discharges, ethosuximide markedly reduced
the frequency of these discharges (Fig. 1D). Thus beha-
vioural and electrographic findings, together with the
observation of ethosuximide sensitivity of SWDs
strongly suggest that BACE1
-/- mice have, in addition to
generalized tonic-clonic seizures, absence seizures simi-
lar to those observed in other rodent models and
human patients.
Increased severity of KA-induced seizures in BACE1
-/-
mice
The finding that a fraction of BACE1
-/- mice have spon-
taneous seizures led us to consider whether pharmaco-
logical induction of seizures might produce different
effects in BACE1
-/- and BACE1
+/+ mice. Kainic acid
(KA) injection is used as an animal model of epileptic
seizures [49]. Injected mice progress predictably through
seizure stages of increasing severity. To test the hypoth-
esis that BACE1
-/- mice have an increased susceptibility
to KA-induced seizures, we injected 3-month-old
BACE1
-/- mice and wild-type littermate controls intra-
peritoneally with 15 mg/kg of KA and observed their
behaviour for 2 hours. This dose was determined by
pilot studies to induce seizures of intermediate severity
in wild-type mice. Seizures were rated by an observer
blinded to genotype according to a modified version of
the Racine scale, varying from 0 (no seizure) to 6 (severe
tonic-clonic seizure)[49]. For each 5-minute interval
post-injection, the highest seizure stage reached was
recorded for each mouse. Beginning at 40 minutes post-
injection, the average seizure stage of BACE1
-/- mice
was greater than that of littermate controls, significantly
so at many time points (Fig. 2A). A seizure sum was
o b t a i n e df o re a c hm o u s eb ya d d i n gt h es e i z u r es c o r e s
from all 5-minute intervals of the 120-minute observa-
tion period. The average seizure sum of the BACE1
-/-
mice was significantly higher than that of littermate
controls (Fig. 2B; 61.6 ± 3.3 vs. 50.2 ± 2.2, p < 0.01, n =
11, 10 respectively).
At the dose of KA used (15 mg/kg), no wild-type mice
had seizures more severe than stage 4. While most
BACE1
-/- mice also reached seizure stages no higher
than stage 4, 3 of 11 mice had more severe seizures
( F i g u r e2 C ) .T h e s em a yr e p r e s e n tas u b s e to fB A C E 1
-/-
mice that are particularly susceptible to excitotoxic
seizures.
BACE1
-/- mice exhibit KA-induced neurodegeneration
A second cohort of mice was injected with a higher dose
of KA (20 mg/kg) to assess the effect of BACE1 genetic
deletion on excitotoxic cell death. All mice had severe
(stage 5-6) seizures with this dose and mortality was
~15%. Brains from these mice were harvested after a
Figure 1 Electoencephalogram (EEG) activity in BACE1
+/+ and BACE1
-/- mice. A. Background spontaneous EEG activity in a BACE1
+/+ and
BACE1
-/- mouse. B. Background EEG activity in BACE1
-/- mouse displays multiple epileptiform abnormalities. SWD, spike-wave discharge. C. EEG
activity during a generalized tonic-clonic seizure in a BACE1
-/- mouse. D. Number of spike-wave discharges (SWDs) per hour observed in BACE1
-/-
mice following administration of 100 mg/kg of ethosuximide or 25 mg/kg of phenytoin; n = 4; **p < 0.01.
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Cresyl violet in order to assess cell loss. The 20 mg/kg
dose did not induce frank neurodegeneration in the hip-
pocampi of any wild-type mice (n = 7). In contrast, a
subset of the BACE1
-/- mice exposed to the high dose of
KA demonstrated obvious cell loss in the CA1/2 region
of the hippocampus (Fig. 3A). This cell loss occurred in
3o ft h e1 0B A C E 1
-/- mice that survived the 7-day
recovery period. In these three brains, there was a nota-
ble thinning of the CA1/2 cell layer and nearly all nuclei
appeared pyknotic throughout the CA1/2 region. The
remaining BACE1
-/- mice and KA-treated BACE1
+/+ lit-
termates did not demonstrate any apparent cell loss
relative to saline-treated controls.
Since KA-induced cell death has been found to
involve DNA fragmentation [50], we performed TUNEL
staining on brain sections as a potentially more sensitive
indicator of cell death. Robust TUNEL labelling was
seen in the CA1/2 region of the hippocampus only in
the mice that showed cell loss by Cresyl violet staining
(Fig. 3B, right). No TUNEL-positive nuclei were
observed in any other region of the hippocampus or the
cortex in these mice. A fourth BACE1
-/- mouse had a
small number of TUNEL-positive nuclei in the CA3
region (not shown). No TUNEL- positive nuclei were
observed in BACE1
-/- mice that did not have cell loss
(not shown) nor in any of the KA-treated wild-type
littermate control mice (Fig. 3B, left; n = 7).
Figure 2 BACE1
-/- mice have increased sensitivity to KA-induced seizures compared to wild-type littermates.B A C E 1
-/- mice and wild-
type littermate controls were injected with 15 mg/kg of KA and observed for 120 minutes. Seizures were rated (0-6) on a modified Racine scale
at each 5-minute interval. A. Average seizure stage for each group over time. B. Sum of all seizure scores over 120 minutes. Error bars indicate
SEM, * p < 0.05, **p < 0.01; n = 10, 11 for BACE1
+/+ and BACE1
-/- groups, respectively. C. Histogram of highest seizure stage reached overall by
each mouse.
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-/-
mice
The finding that BACE1 cleaves the b-subunits of vol-
tage-gated sodium channels suggested a potential
mechanism by which BACE1 might affect neuronal
excitability [22,23]. To determine whether altered levels
of voltage-gated sodium channels in the brain are
responsible for the hyperexcitability of BACE1
-/- mice,
we performed Western blot analysis on brain homoge-
nates from BACE1
-/- mice and BACE1
+/+ littermates.
Given the apparent presynaptic localization of BACE1
[13,51], we specifically examined Nav1.2, an alpha subu-
nit with axonal distribution in the CNS [34]. A Western
blot of whole brain homogenates shows similar levels of
Nav1.2 as well as Nav1.6, the other prominent axonal
CNS a-subunit, in the brains of BACE1
-/- mice and
wild-type littermate controls (Fig. 4A). Quantification
showed no significant difference in either case (Nav1.2:
100 ± 7.0 (+/+) vs 108.7 ± 6.1 (-/-), Nav1.6: 100 ± 3.7
(+/+) vs 98.0 ± 7.9 (-/-), n = 6).
Our characterization of the seizure phenotype demon-
strated a large variability within the group of BACE1
-/-
mice in their susceptibility to seizure/excitotoxicity. We
therefore tested the hypothesis that the subset of
BACE1
-/- mice that appear particularly susceptible have
an increase in brain sodium channel levels that is not
apparent in the group as a whole. To this end we first
compared hippocampal homogenates from the brains of
mice we had characterized with EEG recordings (Fig.
4C,D). These included 2 mice that demonstrated
Figure 3 KA-induced cell death in BACE1
-/- mice. Mice were injected with 20 mg/kg of KA and recovered for 7 days before brains were
harvested and sectioned. A. Cresyl violet staining reveals extensive degeneration in the CA1/2 region of the hippocampus in some BACE1
-/-
mice (right) but no BACE1
+/+ littermates (left). 3 of 10 BACE1
-/- mice had cell loss as demonstrated. 0 of 7 wild-type mice had cell loss. Lower
panels are higher magnification images of region indicated by box in upper panels. B. TUNEL staining performed on adjacent sections indicates
DNA fragmentation in many cells of the CA1/2 region in 3 of 10 BACE1
-/- mice (right). No TUNEL-positive cells were seen in any of 7 KA-treated
wild-type littermates (left) nor in BACE1
-/- mice that lacked cell loss.
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-/- mouse brain. Whole brain or hippocampal homogenates from
BACE1
-/- mice and wild-type littermate controls were resolved by SDS-PAGE for Western analysis with antibodies against Nav1.2 and Nav1.6.
Samples in A and B are whole brain homogenates from naïve animals; Samples in C and D are hippocampal homogenates from mice subjected
to EEG recordings; Samples in E and F are whole brain homogenates from mice injected with 15 mg/kg (top) or 20 mg/kg (bottom) KA. Panels
B, D and F are quantifications of sodium channel signals performed on the blots in panels A, C and E, respectively. No significant differences
were detected in any comparison. All measures were normalized using b-tubulin signal. Error bars indicate SEM. In C, * indicates mice that
exhibited spontaneous seizures and # indicates mice that exhibited abnormal background/spiking on EEG. In E, mice with seizure >4 (high
seizure) and cell loss are indicated.
Hitt et al. Molecular Neurodegeneration 2010, 5:31
http://www.molecularneurodegeneration.com/content/5/1/31
Page 6 of 14spontaneous seizures (*) and 2 mice with abnormal
background/spiking (#), as well as 4 with normal EEGs.
No significant difference in Nav1.2 levels in BACE1
-/-
hippocampi compared with wild-type littermate controls
was observed, either in those with abnormal EEGs or in
the group as a whole (Fig. 4D) (+/+: 100 ± 8.3, n = 5,
-/-: 116.9 ± 4.1, n = 8, EEG abn.: 111.5 ± 7.2, n = 4).
We next compared brain homogenates from the
cohorts of mice treated with 15 mg/kg and 20 mg/kg
KA (Fig 4E). The low dose cohort included a subset of
3 mice that reached seizures t a g e s> 4 ,w h i l et h eh i g h
dose cohort included the 3 mice that demonstrated
frank cell loss in the hippocampus. In both 15 mg/kg
and 20 mg/kg KA groups, no differences in Nav1.2 levels
were seen in either the BACE1
-/- group or the sub-
groups that showed increased susceptibility (Fig. 4F)
(+/+: 100 ± 5.4, -/-: 94.9 ± 7.3, -/- seiz. > 4: 100.5 ± 6.6,
n = 11, 10, 3 respectively; +/+: 100 ± 4.8, -/-: 100.5 ±
5.2, -/- cell loss: 107.7 ± 0.9, n = 7, 10, 3 respectively).
While our results demonstrate a large degree of variabil-
ity in protein levels of voltage-gated sodium channels in
mouse brain, such levels do not correlate with BACE1
genotype nor seizure phenotype.
Nav1.2 levels in mossy fibers do not correlate with
seizure phenotype
Some reports suggest that BACE1 may have different or
even opposite effects on sodium channel expression
levels versus cell surface localization [35,52]. Although
we found total protein levels of Nav1.2 to be unchanged
in BACE1
-/- brains, we considered that altered sodium
channel density on the surface of axons might underlie
the hyperexcitability phenotype. To initially investigate
this, we labelled Nav1.2 in coronal brain sections of
naïve mice using fluorescent antibodies and analyzed
confocal images of the hippocampus. We examined the
stratum lucidum in CA3 (Fig. 5A, slu), which contains
the axons of the mossy fiber pathway, since robust
BACE1 expression is seen in the mossy fiber pathway
[13,51]. Quantitative analysis of fluorescence intensity in
the stratum lucidum indicated that there is no signifi-
cant difference between Nav1.2 levels in BACE1
-/- brains
relative to wild-type littermates (Fig. 5B; +/+: 100 ± 2.0,
-/-: 109.9 ± 7.0, n = 3).
To determine whether differences in axonal sodium
channel levels might account for the variability of sei-
zure outcomes, the subgroups with abnormal EEGs,
severe seizures, and KA-induced cell loss were analyzed
separately. No significant difference was detected
between Nav1.2 levels in the stratum lucidum of
BACE1
-/- brains versus BACE1
+/+ brains, nor did those
mice that had spontaneous seizures and/or abnormal
spiking on EEG have higher Nav1.2 levels than the
BACE1
-/- group as a whole (Fig. 5C, D) (+/+: 100 ± 6.6,
n = 5; -/-: 112.2 ± 3.7, n = 13; EEG abn.: 109.2 ± 7.8,
n = 5). Similarly, the BACE1
-/- mice that reached seizure
stages >4 when treated with 15 mg/kg KA did not have
greater stratum lucidum Nav1.2 levels than other
BACE1
-/- mice, and the BACE1
-/- group did not vary
significantly from wild-type mice (Fig. 5E, F) (+/+: 100 ±
3.0, n = 3; -/-: 114 ± 5.7, n = 6; seiz. > 4: 110.6 ± 11.8, n
= 3). On the other hand, BACE1
-/- mice that incurred
cell loss following treatment with 20 mg/kg KA had sig-
nificantly less Nav1.2 staining in stratum lucidum than
wild-type littermates (Fig. 5G, H) (+/+: 100 ± 4.5, n = 3;
-/-: 92.2 ± 6.0, n = 6; cell loss: 84.5 ± 2.6, p = 0.04 rel.
to +/+, n = 3). This is most likely due to KA-induced
axonal degeneration.
Discussion
While the role of BACE1 in the production of Ab makes
it a key enzyme in AD pathogenesis, little is known
about its normal physiological function. A better under-
standing of the consequences of BACE1 deficiency will
aid in the design of therapeutic strategies to abrogate
Ab generation with minimal adverse effects. Our results
demonstrate that genetic deletion of BACE1 in mice
leads to an increased susceptibility to spontaneous and
pharmacologically-induced seizures. The observation of
rare spontaneous tonic-clonic seizures in BACE1
-/- mice
prompted us to monitor a cohort of these mice with
simultaneous EEG/video recordings. Our data indicate
that a subset of BACE1
-/- mice are epileptic, with spon-
taneous epileptiform abnormalities occurring in ~30% of
animals studied by video and EEG. Of the animals with
epileptiform abnormalities, 80% exhibited spike-wave
discharges and behavioural pauses consistent with
absence seizures, whereas 40% were observed to have
generalized tonic-clonic convulsions. Because our
recording was limited to 5 days of continuous recording,
it is possible that a higher proportion of animals with
abnormal EEGs could also have spontaneous generalized
tonic-clonic seizures. Longer recording periods and eva-
luation of age-dependent changes in seizure patterns are
planned for future studies that will allow better charac-
terization of the seizure phenotypes present in these
animals.
The anatomical basis for epilepsy in the BACE1
-/-
mice is unclear. SWDs and absence seizures are thought
to represent aberrant function in the circuitry that reci-
procally connects the thalamus and cortex (for review,
see [53]). Along these lines, abnormal excitability of tha-
lamocortical neurons, cortical pyramidal neurons, and
intrathalamic inhibitory neurons have each been sug-
gested to contribute to genesis of seizures in models of
absence epilepsy. At the molecular level abnormal func-
tion of T-type voltage gated calcium channels, hyperpo-
larization-activated cyclic nucleotide-gated channels,
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Page 7 of 14Figure 5 NaV1.2 levels in mossy fibers do not correlate with seizure measures. Immunofluorescence labelling of Nav1.2 was performed on
30 μm brain sections, and confocal images of the CA3 region of the hippocampus were obtained. slu, stratum lucidum; DG, dentate gyrus.
Sections in A are representative images from naïve mice, C, from mice subjected to EEG recordings, E, from mice treated with 15 mg/kg KA, and
G, from mice treated with 20 mg/kg KA. Panels B, D, F and H are histograms representing quantifications of Nav1.2 fluorescence intensity in the
stratum lucidum measured by ImageJ of all mice from the groups indicated. Mean fluorescence intensity within the stratum lucidum was
measured and averaged over 2-4 sections/brain. In D, F, and H the subgroups with EEG abnormalities (EEG abn.) and severe seizures (high seiz.)
did not have higher axonal Nav1.2 levels than the BACE1
-/- group as a whole (middle bars). BACE1
-/- mice with cell loss following 20 mg/kg KA
treatment had significantly reduced Nav1.2 in the stratum lucidum. Error bars indicate SEM. n = 3 brains in B; n = 5, 13, 5 resp. in D;n=3 ,6 ,3
resp. in F; n = 3, 6, 3 resp. in H. * p < 0.05. (no seiz., mice with no seizures; spon. seiz., mice with spontaneous seizures; seiz. ≤4, mice with
seizures less than or equal to stage 4; seiz. >4, mice with seizures greater than stage 4)
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of glutamatergic and GABAergic neurotransmission
have been implicated as playing a role in absence sei-
zures. Apart from absence seizures, BACE1
-/- mice also
demonstrate more severe seizures and hippocampal
injury following administration of KA, suggesting that
abnormal excitability is not restricted to neurons
involved in thalamocortical pathways. Furthermore,
BACE1
-/- mice also exhibit generalized tonic-clonic sei-
zures. Understanding whether these convulsive seizures
in BACE1
-/- mice are a result of generalized neuronal
hyperexcitability leading to generalized synchronous
brain activity at seizure onset, or begin with abnormal
synchrony in one or more focal regions of brain, is a
goal of future research.
The fact that electrographic and video evidence of
spontaneous tonic-clonic seizures was only obtained for
2o ft h e1 6B A C E 1
-/- mice that we monitored indicates
a low penetrance of the seizure phenotype in the
BACE1
-/- population. Additional BACE1
-/- mice dis-
played other abnormal findings on EEG such as single
spikes and polyspike complexes; however these still
represent a minority of BACE1
-/- mice (5 of 16, ~31%).
This incomplete penetrance suggests that while BACE1-
deficiency contributes to seizure susceptibility, mediating
factors exist that have yet to be determined. Given that
the BACE1
-/- mice are maintained on an inbred C57/
BL6 background, such factors are likely to be develop-
mental/environmental.
The results of our studies using mice treated with the
glutamate analogue kainic acid (KA) reveal a similar
incompletely-penetrant phenotype in the BACE1
-/- mice.
BACE1
-/- mice treated with 15 mg/kg of KA had signifi-
cantly higher ratings of seizure severity on average than
BACE1
+/+ littermates. However, the highest seizure stage
reached by most BACE1
-/- mice was stage 3 or 4, as seen
in wild-type mice. A subset of 3 of 11 (~27%) BACE1
-/-
mice reached seizure stage 5 or 6, which is atypical at
this dose of KA. This again suggests that a fraction of
BACE1
-/- mice have a particularly marked increase in
their susceptibility to seizures. Similarly, 3 of 10 (30%)
BACE1
-/- mice injected with 20 mg/kg of KA displayed
extensive excitotoxic cell death in the CA1/2 region of
the hippocampus. No cell loss was seen in the remaining
BACE1
-/- mice nor in any of the treated BACE1
+/+ litter-
mates. While it is not clear whether the subgroups from
these three experiments repr e s e n tt h es a m ep o p u l a t i o n ,
the finding of an incomplete penetrance of approximately
30% is consistent across different measures of susceptibil-
ity to seizure and excitotoxicity, highlighting the exis-
tence of additional factors mediating the expression of
this phenotype in BACE1
-/- mice.
The cleavage by BACE1 of the b-subunits of VGSCs
has been purported to alter the expression and
localization of VGSC a-subunits [35], effects that may
bear on the hyperexcitability phenotype discussed here.
We addressed this possibility by examining Nav1.2
expression levels in the brain and localization to the
axons of the mossy fiber pathway in the hippocampus.
We chose this approach because of the high concentra-
tion of BACE1 in the mossy fiber presynaptic terminals
[13,51] and the particular susceptibility of hippocampal
neurons to excitotoxicity in seizure models [50]. Our
results indicate that brain levels of Nav1.2 protein are
no different in BACE1
-/- mice relative to BACE1
+/+
mice, though there was a large degree of variability
between mice. In addition, protein levels of Nav1.2 from
the brains of mice identified by our EEG and KA-injec-
tion experiments as particularly susceptible to seizure
and excitotoxic injury did not differ from those of
BACE1
+/+ mice or BACE1
-/- mice as a whole. Similar
results were obtained from our measurements of the
intensity of immunofluorescent labelling of Nav1.2 in
the stratum lucidum (the location of mossy fiber axons).
There was no statistically significant difference between
Nav1.2 staining in the mossy fibers of BACE1
-/- mice
and those of BACE1
+/+ mice, and axonal Nav1.2 levels
were not higher in mice with EEG abnormalities or
severe KA-induced seizures than in BACE1
-/- mice as a
whole. Thus, while there is large variation across the
BACE1
-/- mouse population in seizure susceptibility as
well as in Nav1.2 expression and axonal localization, our
results find no correlation of these measures and do not
support the hypothesis that altered Nav1.2 expression or
localization underlies the hyperexcitability phenotype of
BACE1
-/- mice.
While we were preparing this manuscript, a study by
Hu et al. was published that reports a similar seizure
phenotype in BACE1
-/- mice and also examines VGSC
expression and function [52]. Hu et al. report that the
fraction of BACE1
-/- mice that develop spontaneous sei-
zures detected by EEG monitoring increases with age,
reaching 21.9% by age >10 months, and find that
BACE1
-/- mice injected with KA tend to reach higher
seizure stages than BACE1
+/+ mice [52]. They present
compelling evidence of increased neuronal excitability in
BACE1
-/- brain slices using extracellular field recordings
and of increased sodium currents and altered firing
properties in dissociated BACE1
-/- neurons using patch-
clamp and current-clamp recordings. In addition, they
report reduced total Nav1.2 protein levels and increased
cell surface expression and mossy fiber localization of
Nav1.2 in BACE1
-/- brains, consistent with the findings
of Kim et al. for Nav1.1 [35]. The characteristics of the
seizure susceptibility phenotype of BACE1
-/- mice that
we present here are quite consistent with those reported
by Hu et al. However, we do not find a reduction in the
total protein levels of VGSC a-subunits (Nav1.2 or
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-/- brains, as reported by Hu et al.
[52]. The cause of this discrepancy is not clear but may
be related to differing extraction methods or the more
robust sample size in our experiments given the high
variability of sodium channel levels between animals. Hu
et al. report a qualitative increase in Nav1.2 immuno-
fluorescent labelling in the stratum lucidum but do not
quantify this increase and do not address the implied
causal link to the seizure/neuronal excitability pheno-
type experimentally. Our quantification of Nav1.2 immu-
nofluorescence intensity in the strata lucida of BACE1
-/-
and BACE1
+/+ brain sections shows no significant differ-
ence and finds that these levels do not correlate with
EEG abnormalities or severity of KA-induced seizures as
one would expect if increased Nav1.2 expression in
axons were responsible for these outcomes.
Our results support the conclusion that VGSC level
and localization in BACE1
-/- mice are insufficient to
account for the predisposition to seizures in these mice.
Thus, further investigation of other potential contribut-
ing mechanisms is warranted. One such mechanism is
the effect of BACE1 on sodium channel gating proper-
ties as reported by Huth et al. [36]. This phenotype may
also be due to the effects of the proteolysis of other pro-
teins identified as BACE1 substrates, such as a2,6-sialyl-
transferase, PSLG-1, APLP1, APLP2, LRP, NRG1 and
NRG3, or currently undiscovered BACE1 substrates.
The hypomyelination purportedly found in the CNS of
BACE1
-/- mice [24] may also contribute. Alternatively,
the seizure susceptibility of BACE1
-/- mice may be sec-
ondary to hypothetically altered formation of synapses
and neural circuits during brain development. There is
robust expression of BACE1i nt h eb r a i nd u r i n ge a r l y
postnatal development [25,54], during which time, pro-
teolysis of BACE1 substrates may play a role in synapse
formation and patterning. Finally, the effect of BACE1
on neuronal excitability may involve the action of Ab at
synapses. It has been observed that Ab is released at
synapses in an activity-dependent manner [55] and that
Ab can negatively regulate excitatory neurotransmission
via reduction of AMPA receptors [56,57]. These pro-
cesses should not be discounted as potential contribu-
tors to the hyperexcitability phenotype observed in
BACE1
-/- mice.
Conclusions
We have demonstrated that a subset of BACE1
-/- mice
displays abnormal brain activity on EEG, occasionally
including spontaneous absence and tonic-clonic seizures.
In addition, BACE1
-/- mice have KA-induced seizures of
greater severity than BACE1
+/+ littermates, and a frac-
tion of KA-treated mice exhibit excitotoxic cell death in
the hippocampus that is not observed in wild-type mice.
While the regulation of VGSCs by BACE1 may
contribute to this seizure-susceptibility phenotype, we
find that neither Nav1.2 expression levels nor axonal
localization correlate with seizure susceptibility, indicat-
ing that alteration of these properties is insufficient to
fully explain the phenotype. Thus, research into other
potential mechanisms is warranted, as is research into
factors that mediate the expression of the phenotype
given its incomplete penetrance. Better understanding of
the effect of BACE1 deficiency on neuronal excitability
and seizure susceptibility has important implications for
BACE1 inhibition as a therapeutic strategy for AD.
Methods
Animals
BACE1
-/- mice were purchased from The Jackson
Laboratory, Bar Harbor, ME, USA (Described in [27]).
Heterozygotes were used for breeding and all litters
were genotyped by PCR using primers listed in the sup-
plementary information of [27]. All wild-type controls
used were BACE1
+/+ littermates. All mice were main-
tained in microisolator cages in the Barrier Facilities of
Northwestern University Center for Comparative Medi-
cine. All animal procedures were in strict accordance
with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and were approved
by the Northwestern University Animal Care and Use
Committee.
Animal surgery, recording, and pharmacology
Animal surgery was performed as described in [46]. In
summary, BACE1
-/- and BACE1
+/+ mice were anesthe-
tized by intraperitoneal injection of xylazine/ketamine
(100 mg/kg/10 mg/kg). The scalp was exposed and four
holes were drilled to the dura: two placed 1 mm ante-
rior to bregma, and two placed 7 mm anterior to
bregma, each was 1.5 mm lateral to the central sulcus.
A prefabricated headmount was attached to the skull
with stainless steel screws and covered with dental
acrylic. Following 1 week of recovery, a preamplifier was
attached to the headmount and a data acquisition sys-
tem (Pinnacle Technology Inc., Lawrence, KS) was used
to record continuous EEG and video in freely moving
mice. BACE1
-/- mice were placed in a recording cham-
ber with food and water and allowed to freely move
while recording. To screen for abnormal paroxysmal
EEG activity BACE1
-/- mice were recorded continuously
for five days. Following acquisition of baseline EEG
activity, mice with abnormal EEG activity were used in
pharmacology studies. BACE1
-/- mice displaying seizure
activity received a single intraperitoneal injection of phe-
nytoin (25 mg/kg; Sigma, St. Louis, MO) or ethosuxi-
mide (Sigma, 100 mg/kg). Spike wave discharges
(SWDs) were scored for 1 hour following injection.
SWDs were characterized as bilaterally synchronous,
Hitt et al. Molecular Neurodegeneration 2010, 5:31
http://www.molecularneurodegeneration.com/content/5/1/31
Page 10 of 14regular (4-6 Hz) multiple-spike complexes with a spike
and wave morphology and amplitudes at least 4 times
higher than average baseline amplitude [58]. Single
spikes were identified as sharp activity with amplitude of
at least 4 times baseline amplitude associated with an
aftercoming slow wave. Polyspike complexes were iden-
tified as multiple independent spikes without associated
wave morphology. EEG activity 1 hour post-injection
was analyzed for SWDs as compared to 1-hour epochs
preceding the injection in the same BACE1
-/- mice.
Kainic acid treatment and seizure assessment
At three months of age, mice received intraperitoneal
injections of either 15 mg/kg or 20 mg/kg kainic acid
(Tocris, Bristol, UK, Cat. 0222) and were observed for
two hours (15 mg/kg) or four hours (30 mg/kg). Seizure
stage was assessed according to a modification of the
Racine scale: stage 0 - normal behaviour; stage 1 -
hypoactivity, immobility; stage 2 - rigidity, whisker
twitching; stage 3 - reared, rigid posture, some automa-
tisms (e.g. forelimb pawing, head bobbing, tail whip-
ping); stage 4 - intermittent rearing and falling with
forelimb/jaw clonus, stage 5 - continuous rearing and
falling >30 s or continuous jumping (popcorning); stage
6 - generalized tonic-clonic seizures with whole body
convulsions. For each five-minute interval the highest
seizure stage reached was recorded.
Histology and TUNEL staining
At seven days post-injection, mice were deeply anesthe-
tized with intraperitoneal injection of ketamine (200
mg/kg)/xylazine (25 mg/kg) and then transcardially per-
fused with HEPES buffer containing protease inhibitors
[20 μg/ml phenylmethylsulphonyl fluoride, 0.5 μg/ml
leupeptin, 20 μM sodium orthovanadate, and 100 μM
dithiothreitol (DTT)] before removal of brains. One
hemibrain per mouse was fixed in 4% paraformaldehyde
(PFA) in PBS for 24 h and then cryopreserved in 30%
(w/v) sucrose for >24 h. 30 μm coronal sections were
cut from PFA-fixed brains on a freezing sliding micro-
tome and collected in 0.1 M PBS with 0.01% sodium
azide. Sections were mounted on slides and stained with
cresyl violet. TUNEL staining was performed on slide-
mounted brain sections surrounded by ImmEdge hydro-
phobic barrier (Vector Laoratories, Burlingame, CA).
Slides were washed in PBS + 0.1% Tween-20 (PBS-T)
between all steps. Tissue was permeabilized by treat-
ment with proteinase K (20 μg/ml) in PBS-T for 30
min., treated with 3% H202 in PBS for 10 min., and
equilibrated in TdT reaction buffer for 10 min. before
incubation in dUTP-biotin (5 μM) and terminal deoxy-
nucleotidyl transferase (TdT) enzyme (2000 U/ml)
(Roche Diagnostics, Mannheim, Germany) in a humidi-
fied chamber at 37°C for 2 hours. Reaction was stopped
by placing slides in 300 mM NaCl, 30 mM Na Citrate
for 10 min. Sections were then incubated in reagents A
and B from Vectastain ABC kit (Vector Laoratories,
Burlingame, CA) (10 μl each per ml PBS-T) for 30 min.,
washed, and incubated in a 1:1 mix of 0.67 ul/ml 30%
H2O2 in H2O: 1 mg/ml 3,3-Diaminobenzidine (DAB) in
PBS for 5 min.. A section treated with reaction mixture
excluding TdT enzyme was used as a negative control
and a section pretreated with DNaseI (3000 u/ml)
(Roche Diagnostics, Mannheim, Germany) was used as a
positive control.
Immunoblotting
Flash-frozen hemibrains or hippocampi were homoge-
nized in PBS 1% Triton-X 100 with 1× Calbiochem Pro-
tease Inhibitor Cocktail Set I (EMD Biosciences, La
Jolla, CA) using a motorized tissue homogenizer (hemi-
brains) or a tube and pestle (hippocampi). Total protein
concentrations of brain homogenates were determined
by the BCA method (Pierce, Rockford, IL). 5 μgp r o t e i n
from brain homogenates was boiled in SDS sample boil-
ing buffer before being separated on 4%-12% NuPAGE
Bis-Tris gels in 1× MOPS running buffer (Invitrogen,
Carlsbad, CA) and transferred to Millipore Immobilon-P
polyvinylidene difluoride (PVDF) membrane (Millipore,
Billerica, MA), as described previously [51]. Blots were
blocked in 5% non-fat dry milk in Tris-buffered saline
(TBS), 0.1% Tween 20 (TBS-T; Sigma) overnight, then
incubated in primary antibody (Nav1.2: Rb pAb, Milli-
pore, AB 5206, 1:1000; Nav1.6: Rb pAb, Abcam, Cam-
bridge, MA, ab65166, 1:500; b-tubulin, Ms mAb,
Millipore, MAB5564, 1:50000) for 1 hr at RT or over-
night at 4°C. Blots were washed in TBST and incubated
for 1 hr in horseradish peroxidase (HRP)-conjugated
goat anti rabbit (Jackson ImmunoResearch Laboratories,
West Grove, PA) or horse anti-mouse (Vector Labora-
tories) secondary antibodies diluted 1:10,000 in 5% milk
in TBST. Immunosignals were detected using enhanced
chemiluminescence (ECL or ECL+, Amersham Bios-
ciences, Piscataway, NJ) and quantified using a Kodak
Image Station 400R imager (Rochester, NY). Densito-
metric analyses of immunoblots were performed using
Kodak Molecular Imaging Software SE. Immunosignals
were normalized to b-tubulin immunosignal. Values
were expressed as percentages of the mean of the con-
trol. Statistical significance was determined using
unpaired two-tailed Student’s t-test to compare each
BACE1
-/- group (total or subset) with BACE1
+/+ con-
trols and two-way ANOVA to compare three groups.
Immunofluorescence labelling and confocal microscopy
Tissue sections were prepared as described above. Sec-
tions with equivalent rostral-caudal locations were
selected using anatomical landmarks and the size and
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(naïve and KA-treated mice) or 4 sections (EEG mice)
were selected per brain. Free-floating sections were
washed in TBS + 0.25% Triton-X 100 and blocked for
90 min. in 5% goat serum before being incubated in pri-
mary antibody (Rb anti-Nav1.2 pAb, Millipore, AB5206,
1:500) in TBS + 0.25% Triton-X 100, 1% bovine serum
albumin (BSA) at 4°C overnight on an orbital shaker.
Sections were then washed in Triton-TBS, 1% BSA and
incubated in 1:10,000 goat anti-rabbit Alexa Fluor 594
antibody (Invitrogen) in Triton-TBS, 1% BSA for
90 min. on an orbital shaker. Sections were washed in
TBS and mounted on slides. Coverslips were applied
with Prolong Gold anti-fade mounting media (Invitro-
gen). Confocal images were acquired using a Nikon
C1Si confocal microscope (Tokyo, Japan) with a 10× air
objective. Laser power percentage, gain, and offset set-
tings were held constant for all images acquired and
saturation was never reached. All images were acquired
during one continuous session to prevent effects of
decay of laser intensity. Images were analyzed using
ImageJ (NIH). The stratum lucidum was outlined in
each image using a freeform marquee and mean bright-
ness was measured within the outlined area. Mean fluor-
escence intensity values for each brain were averages of
sections from the same brain and means and SEMs
were calculated for each treatment group. Values were
expressed as percentages of the mean of the control.
Statistical significance was determined using unpaired
two-tailed Student’s t-test to compare each BACE1
-/-
group (total or subset) with BACE1
+/+ controls and
two-way ANOVA to compare three groups.
Additional material
Additional file 1: Video 1. Video monitoring and corresponding EEG
trace of BACE1-/- mouse exhibiting typical generalized tonic-clonic
seizure.
Additional file 2: Video 2. Video monitoring of the onset of 3
distinct generalized tonic-clonic seizures in BACE1
-/- mice,
demonstrating atonia at seizure onset.
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